Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharm Stat. 2012 Nov-Dec;11(6):476-84. doi: 10.1002/pst.1539. Epub 2012 Sep 25.

A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis.

Author information

1
Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, UK.

Abstract

We describe a dose escalation procedure for a combined phase I/II clinical trial. The procedure is based on a Bayesian model for the joint distribution of the occurrence of a dose limiting event and of some indicator of efficacy (both considered binary variables), making no assumptions other than monotonicity. Thus, the chances of each outcome are assumed to be non-decreasing in dose level. We applied the procedure to the design of a placebo-controlled, sequential trial in rheumatoid arthritis, in each stage of which patients were randomized between placebo and all dose levels that currently appeared safe and non-futile. On the basis of data from a pilot study, we constructed five different scenarios for the dose-response relationships under which we simulated the trial and assessed the performance of the procedure. The new design appears to have satisfactory operating characteristics and can be adapted to the requirements of a range of trial situations.

PMID:
23011957
DOI:
10.1002/pst.1539
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center